This Article Full Text (PDF) All Versions of this Article: 1756287209105264v1 1/2/67    most recent References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Bahnson, E. E. Articles by Bahnson, R. R. Search for Related Content Social Bookmarking                         What's this?

PET/CT imaging of clear cell renal cell carcinoma with 124I labeled chimeric antibody

Department of Radiology, The Ohio State University, Columbus, OH 43210, USA

Douglas A. Murrey, Jr, MD

Department of Radiology, The Ohio State University, Columbus, OH 43210, USA

Cathy M. Mojzisik, RN, MS

Department of Radiology, The Ohio State University, Columbus, OH 43210, USA

Nathan C. Hall, MD, PhD

Department of Radiology, The Ohio State University, Columbus, OH 43210, USA

Humberto J. Martinez-Suarez, MD

Department of Urology, The Ohio State University, Columbus, OH 43210, USA

Michael V. Knopp, MD, PhD

Department of Radiology, The Ohio State University, Columbus, OH 43210, USA

Edward W. Martin, Jr, MD

Department of Surgical Oncology, The Ohio State University, Columbus, OH 43210, USA

Stephen P. Povoski, MD

Department of Surgical Oncology, The Ohio State University, Columbus, OH 43210, USA

Robert R. Bahnson, MD

Department of Urology, The Ohio State University, Columbus, OH 43210, USA, robert.bahnson{at}osumc

Clear cell renal cell carcinoma (ccRCC) presents problems for urologists in diagnosis, treatment selection, intraoperative surgical margin analysis, and long term monitoring. In this paper we describe the development of a radiolabeled antibody specific to ccRCC (124I-cG250) and its potential to help urologists manage each of these problems. We believe 124I-cG250, in conjunction with perioperative Positron emission tomography/ computed tomography imaging and intraoperative handheld gamma probe use, has the potential to diagnose ccRCC, aid in determining a proper course of treatment (operative or otherwise), confirm complete resection of malignant tissue in real time, and monitor patients post-operatively.

Key Words: advanced kidney cancer • kidney cancer basic research • kidney cancer evaluation/staging • kidney cancer localized • kidney cancer

This version was published on June 1, 2009

Therapeutic Advances in Urology, Vol. 1, No. 2, 67-70 (2009)
DOI: 10.1177/1756287209105264


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?